Sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus: assessing safety and effectiveness using real-world data
Please join us …
When: Tuesday, April 3, 2018, 12–1 p.m.
Where: ICES, G-Wing, Conference Centre (Sunnybrook Health Sciences Centre)
Who: Dr. Michael Fralick, MD, FRCPC, MSc; General internist at St Mike’s; PhD Candidate at IHPME.
Topic: Sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus: assessing safety and effectiveness using real-world data
Learning objectives
- Learn about the mechanism of action and benefits of SGLT2s
- Discuss the known risks of SGLT2s
- Discuss my planned PhD thesis on understanding the risks and benefits of SGLT2s using real-world data.
Michael Fralick